Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors

Summary

Cetuximab is an EGFR inhibitor that has shown efficacy alone or in combination in colorectal cancer or head and neck cancer in several phase II/III studies. Temsirolimus is a new mTOR inhibitor that has shown interesting results in several Phase I/II studies in advance kidney cancer of bad prognosis. Study hypothesis is that combination of those two compounds and the inhibition of two pathways at the same time will have more efficiency on tumoral growth than the inhibition of those pathways in isolation.

Timeline

Start

2011-04-26

Primary completion

2014-09-15

Completion

2016-05-04

Drugs

Indications

No indication recorded.